Back بيوأنتك Arabic بيوانتك ARZ BioNTech Azerbaijani BioNTech Byelorussian BioNTech BS BioNTech Catalan BioNTech Czech Biontech Danish Biontech German BioNTech Greek
 | |
 Headquarters in Mainz | |
| Company type | Public |
|---|---|
| Nasdaq: BNTX | |
| ISIN | US09075V1026 |
| Industry | Biotechnology |
| Founded | 2008 |
| Founders |
|
| Headquarters | , Germany |
Number of locations | 17 (2024[1]) |
Area served | Worldwide |
Key people |
|
| Products | Pfizer-BioNTech COVID-19 vaccine, Immunotherapy and vaccine candidates |
| Services | Immunotherapy |
| Revenue |  €2.751 billion (2024) |
| €−1.31 billion (2024) | |
| €−665 million (2024) | |
| Total assets | €22.53 billion (2024) |
| Total equity | €19.41 billion (2024) |
Number of employees |  6,772 (2024) |
| Website | biontech |
| Footnotes / references BioNTech FY 2024 report[2] | |
BioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek[3] short for Biopharmaceutical New Technologies) is a global biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology[4][5] testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic.[6][7]
- ^ "Locations". BioNTech. Retrieved 14 December 2024.
- ^ "BioNTech 2024 Annual Report (Form 20-F)". U.S. Securities and Exchange Commission. 10 March 2025. Retrieved 11 March 2025.
- ^ "BioNTech CEO on vaccine progress with Pfizer – YouTube". Retrieved 14 June 2021 – via YouTube.
- ^ BioNTech SE (9 September 2019), "Form F-1", U.S. Securities and Exchange Commission, archived from the original on 14 February 2021, retrieved 23 September 2020
- ^ Amy Baxter (14 August 2024). "Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope". PharmaVoice. Retrieved 15 December 2024.
- ^ "Covid-19: Studies Indicate Pfizer-BioNTech Vaccine Protects Against the Most Severe Outcomes of Some Virus Variants". The New York Times. 5 May 2021. Retrieved 14 December 2024.
- ^ Hannah Devlin, Julia Kollewe (26 November 2021). "BioNTech says it could tweak Covid vaccine in 100 days if needed". The Guardian. Retrieved 14 December 2024.